Abstract
Introduction
Cardiac resynchronization therapy (CRT) has become a cornerstone in the treatment of chronic heart failure (CHF) [1, 2] . Indeed, several clinical trials observed a reduction in morbidity and mortality as compared to medical therapy alone in patients suffering from symptomatic left ventricular (LV) dysfunction (LV ejection fraction [LVEF] £ 35%) with a prolonged QRS duration (≥ 120 ms).
Nevertheless, almost 30% of patients do not exhibit an improvement in clinical symptoms or hemodynamic parameters after CRT implantation (so-called "non-responders") [3] . This lack of improvement may be due to pre-implantation characteristics such as large areas of scar tissue due to coronary artery disease or a lack of mechanical dyssynchrony [4] . Suboptimal LV lead position further represents a reason for a lack of benefit [4] . Additionally, however, some patients do not respond to CRT due to suboptimal CRT device settings, impairing LV filling (atrioventricular [AV] dyssynchrony) and/or persistent LV dyssynchrony [5] .
At the University Hospital of Zurich, we implemented a standard protocol by which every patient with a CRT device undergoes a complete device optimization 3-6 months after implantation and again on a yearly basis or if clinically deemed necessary. The goal of the present study was to summarize clinical presentation, echocardiographic findings, and device settings from CHF patients undergoing CRT optimization in this "real world" setting, unraveling the amount of patients presenting with suboptimal settings, as well as the parameters most frequently requiring adjustment. We provide a rationale for the necessity of implementing a routine protocol for the integrated management of these complex CHF patients, including expert device management.
Methods

Study population and CRT implantation
All patients with a CRT device receiving their first device follow-up in our specialized device clinic from January 1 st 2011 until September 2012 were prospectively included. The study was approved by the cantonal ethics committee Zurich. Mean time from implantation to optimization was 2.9 months (Table 1) . Indications for CRT implantation were based on current guidelines [1] . CRT devices were implanted by a standard procedure under local anesthesia. Devices and leads from Biotronik, Boston Scientific/Guidant, Medtronic and St. Jude Medical were used. For implantation of the LV lead, percutaneous placement into a lateral or postero-lateral vein was attempted whenever possible. If no suitable vein branch was available, epicardial lead implantation was performed.
Follow-up protocol
We implemented a standard protocol by which every patient with a CRT device underwent a comprehensive and standardized device follow-up and optimization procedure (Fig. 1) . After a complete clinical assessment by a heart failure specialist, a comprehensive device follow-up was performed by implantable electronic cardiac device specialists (JS/DH), including complete check of the system with 12-lead electrocardiogram (ECG), and review of all brady-and tachycardia parameters. Subsequently, a complete echocardiographic exam was performed (Vivid E9, GE), followed by optimization of the AV-and interventricular (VV) delay if necessary. AV delay optimization was performed starting at a long AV-delay without intrinsic conduction. The AV-delay was then progressively shortened in steps of 20 ms until truncation of the A-wave was observed. Then, the AV-delay was prolonged in 10 ms steps until the optimal separation of E/A wave without truncation of the A-wave was reached, which was considered the optimal AV-delay.
Results
Study population
A total of 170 CHF patients were included in this prospective analysis. Baseline demographic data at implantation, as well as clinical characteristics at time of follow-up are summarized in Table 1 . The majority of patients were men (76.5%), and had a cardiovascular risk profile typical of a real--world CHF cohort as previously shown [6] . All patients were on optimal medical therapy including angiotensin converting enzyme-inhibitors or angiotensin-II-blockers (95.2%), beta-blockers (93.5%) and diuretics (86.3%) prior to implantation. Furthermore, more than 50% of patients were treated with an aldosterone antagonist (55.4%) in addition to standard diuretic therapy, and received anti-arrhythmic treatment with either digitalis (13.1%) or amiodarone (17.9%) ( Table 2 ).
Echocardiographic and electrocardiographic parameters at follow-up
Most patients demonstrated a reduced LVEF (mean 37.3 ± 11.1%) and a dilated LV (end-diastolic volume index 88.4 ± 41.6 mL/m 2 ; Table 3 ). Of note, parameters of dyssynchrony at this time mainly demonstrated values within our lab's predefined normal values (interventricular mechanical delay -IVMD < 40 ms, tissue Doppler imaging -TDI septal-lateral < 60 ms, TDI anteroseptal-posterolateral < 60 ms), with an IVMD of 17.5 ± 27.7, as well as 32.7 ± 46.8 ms and 33.5 ± 46.3 ms for septal-lateral and anteroseptal-posterolateral delay assessed by TDI, respectively. The mean intrinsic QRS duration was 150 ± 26.6 ms with an ECG pattern of left bundle branch block in the majority of cases (59.5%), and an average PQ interval of 184.7 ± ± 27.6 ms (Table 4) . At the time of implantation and at the first follow-up, most patients were in sinus rhythm (65.9%). While 65.3% of the patients had the same rhythm at our follow-up visit, a minority of patients switched from atrial fibrillation to sinus rhythm (2.4%) and vice versa (4.8%).
Device settings and intervals at the time of optimization
True biventricular pacing was present in nearly half of the patients at the time of optimization (44.7%), while QRS fusion could be detected in 39.4% of cases (Table 5 , Fig. 2 ). At the time of optimization, average sensed AV (sAV) delay was 110.5 ± 19 ms and paced AV (pAV) 136.5 ± 23.4 ms. QRS fusion, as diagnosed by 12-lead surface ECG, began to appear at an average sAV of 103.9 ± ± 37.1 ms and an average pAV of 136.5 ± 23.4 ms, respectively.
A biventricular pacing rate of more than 95% was present in 85.8% of patients from the studied cohort. The main reason for a low biventricular pacing percentage was either atrial fibrillation or 
Left ventricular lead settings
In a third of all cases, lead pacing configuration was "true" bipolar from the LV lead tip (LvTip) to the LV ring (LvRing; 34.1%) or between LvTip to the right ventricular lead ring (RvRing; 28.2%, Table 6 ). In every fifth patient, the pacing vector was between the LvTip and the coil of the right ventricular lead (RvCoil; 23.5%). With these configurations, only a minority of patients (n = 7, 4.2%) were suffering from diaphragmatic capture (4.2%), which was solved in all cases by reprogramming. 
Optimization of CRT settings after implantation
In the majority of all patients who underwent CRT device implantation, the programmed AV intervals were deemed suboptimal during follow-up and were subsequently reprogrammed (Table 7) . AV delays were shortened (sAV delay in 53.3%, pAV delay in 38.1% of the patients) mainly due to the presence of QRS fusion on the 12-lead ECG. In contrast, the AV delay was prolonged in only 17.5% and 28.4% (sAV and pAV, respectively), mostly due to truncation of the A wave in the LV inflow pulse wave Doppler measurement. In 77 patients (45% of the entire cohort), some degree of QRS fusion was accepted in order to allow for better LV filling.
In contrast to the adjustments of the AV interval, the VV delay was left unchanged in the majority of patients (88.1%). The main reason for a change in VV delay was intraventricular dyssynchrony observed on TDI (82.4%).
Thirty three (19.4%) patients in our cohort suffered from atrial fibrillation. By virtue of this, AV optimization was impossible in these patients and VV optimization greatly impaired. Of our patients with atrial fibrillation, 20 (61%) had intrinsic conwww.cardiologyjournal.org duction, whereas 7 (21.2%) and 6 (18.2%) patients had no intrinsic AV conduction or had undergone AV node ablation, respectively (Table 4) .
Discussion
The aim of the present study was to give an overview on CRT settings at the time of device implantation and to demonstrate the potential for optimization by comprehensive assessment during follow-up in an integrative device clinic. In view of the substantial discrepancy between programmed parameters and optimal values, our data indicate that this opportunity is frequently missed in the "real world", providing a rationale for the necessity of protocol-oriented expert follow-up and optimization procedures for these patients.
AV delay optimization and QRS fusion
Whether and how AV intervals should regularly be evaluated and adjusted remains a matter of debate [7] [8] [9] . In various preliminary studies, optimization of the AV delay has been demonstrated to significantly increase hemodynamic response, New York Heart Association (NYHA) class, LVEF and B-type natriuretic peptide level in the short-time follow-up [10] [11] [12] [13] [14] . In contrast, the recently published SmartDelay determined AV Optimization: A comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV) trial implied otherwise. In this study, CRT device recipients were randomized to a fixed empirical AV delay of 120 ms, an echocardiographically optimized AV delay or a device-based AV optimization algorithm (SmartDelay) [15] . The primary endpoint, LV end-systolic volume at 6 months after implantation did not differ between the 3 groups. As discussed by the authors, it may be possible that the observed acute beneficial hemodynamic effects after CRT implantation are not sufficient enough to result in an improvement of hard clinical endpoints. On the other hand, the follow-up period of only 6 months may have been too short to evaluate such endpoints.
Furthermore, it has to be kept in mind that the optimal AV delay may have a high variability among CRT patients [5, 16] . As such, data from SMART-AV do not imply that individual patients with suboptimal AV delay may not profit from an optimization procedure. Indeed, this has been substantiated most recently in a subanalysis from MADIT-CRT, in which patients with short AV-delays (notably < 120 ms) had a superior outcome compared to those with longer AV delays [17] . Our data demonstrate that programming an empirical setting of 120 ms for the sensed AV delay was suboptimal in terms of true biventricular stimulation in the vast majority of patients (57.1%), and 8 (5.7%) patients even demonstrated entirely intrinsic conduction or pseudofusion (and hence loss of biventricular pacing) at this setting. Furthermore, a subanalysis of the Clinical Evaluation on Advanced Resynchronization (CLEAR) pilot study revealed that systematic CRT optimization was associated with a higher percentage of improved patients based on the composite endpoint (all-cause mortality, heart failure-related hospitalization, NYHA functional class, and quality of life score), fewer deaths and fewer hospitalizations [18] . These data clearly indicate a role for CRT optimization over standard programming in all patients. Moreover, the mean interatrial delay was markedly longer (71.9 ± 28.2 ms; Table 5 ) than the standard programmed difference between sensed and paced AV delay (usually 30-40 ms) found in the default settings, further supporting an individualized approach to AV delay programming.
The majority of our patients (> 70%) underwent reprogramming of the AV delay. One of the most important parameters to guide AV delay optimization is the level of true biventricular pacing or, vice versa, the degree of QRS fusion as a result of intrinsically conducted ventricular excitation [19] [20] [21] . In our cohort, 45.3% of patients presented with an AV delay too long to avoid any QRS fusion. However, whether some degree of ventricular fusion may be clinically beneficial remains a matter of debate, as a certain amount of QRS fusion has been shown to improve hemodynamics [22] [23] [24] . Fusion allows for intrinsic excitation of the right ventricle via the normal-conducting right bundle branch which may result in improved right ventricle contraction [25] . A recent study further demonstrated that the maximal rate of LV pressure increase (dP/dt) was higher in LV pacing combined with intrinsic conduction as compared to biventricular pacing [22] . Based on these data, we accepted some degree of QRS fusion in order to allow for optimal LV filling in those cases where it was impossible to shorten the AV delay to the point of complete loss of QRS fusion (Fig. 2) . Importantly, intrinsic conduction and pseudofusion could entirely and sustainably be avoided in all patients presenting with these findings.
VV delay optimization
For various reasons, VV delay optimization appears to be less important as compared to AV delay optimization. Even though an improvement in hemodynamic conditions has been observed after optimization of VV intervals [26] [27] [28] , other randomized trials failed to find a beneficial effect [29, 30] . The latter may, at least in part, be due to the fact that VV delay optimization was performed in the majority of patients on top of AV delay optimization. In a small study investigating the effect of simultaneous AV and VV time optimization, an additional but smaller beneficial effect of VV delay optimization was found [31] . In our cohort, only a minority of patients underwent VV optimization, mainly due to the fact that it was not deemed necessary due to satisfying echocardiographic dyssynchrony parameters and, coherently, visual impression of synchronous LV contraction. In patients who were optimized, the indication was mainly driven by TDI values during echocardiographic evaluation. Conversely, 30 (17.9%) patients were dyssynchronous either visually or by TDI measurements, but could not be corrected by advancing left or right ventricle activation. As a result, and due to the lack of clear evidence for a benefit, VV optimization is only performed in special cases in our institution.
CRT in patients with atrial fibrillation 19 .4% of patients in our cohort suffered from atrial fibrillation. These patients pose a challenge in CRT as the uncoordinated and often rapid intrinsic conduction often results in a substantially impaired rate of biventricular pacing (< 95%). Indeed, atrial fibrillation was the main reason for a low percentage of biventricular pacing in our cohort. Pharmacologically, amiodarone has been shown to be most effective and safe for rhythm control in atrial fibrillation patients with heart failure [32] , and, as a consequence, is frequently used to increase the percentage of biventricular stimulation. If the medical therapy is insufficient, AV nodal ablation is recommended as the next step [33] . In our cohort, 39.4% of patients with atrial fibrillation ultimately had no intrinsic AV conduction and, consequently, had a high degree of biventricular pacing.
Limitations of the study
Our study has some inherent limitations. Data are only collected from a single tertiary care center, and may hence not be generalizable to other healthcare settings. We do, however, believe that most interpretations and statements characteristically reflect the situation of "real world" CRT patients, and are therefore important for therapy optimization of these individuals. The study is further limited by the fact that we focused on the necessity and possibilities for CRT optimization, and as such did not assess clinical or echocardiographic outcome in these patients, which was beyond the scope of this study. However, evidence is accumulating as indicated above that empirical AV delay programming cannot generally be recommended [17] . As such, our data do indicate that specialist follow-up of CRT recipients is of crucial importance in order to provide optimal care for these complex patients, which was the primary aim of the current study.
